Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding (Q26829251)

author

Jolanta M Siller-Matula

Jolanta Siller-Matula

12

0 references

Jean-Luc Reny

Jean-Luc Reny

20

0 references

Rossella Marcucci

Rossella Marcucci

19

0 references

Ajay J Kirtane

11

Ajay Kirtane

1 reference

16

Ron Waksman

1 reference

7

Gregg W. Stone

1 reference

15

Deepak L. Bhatt

1 reference

21

Dietmar Trenk

1 reference

1

Udaya S. Tantry

1 reference

2

Laurent Bonello

1 reference

3

Daniel Aradi

1 reference

5

Young-Hoon Jeong

1 reference

10

Jurrien ten Berg

1 reference

Dimitrios Alexopoulos

18

Dimitrios Alexopoulos

1 reference

22

Dirk Sibbing

1 reference

14

Richard C. Becker

1 reference

6

Dominick J. Angiolillo

1 reference

23

Paul A. Gurbel

1 reference

9

Tobias Geisler

1 reference

Matthew J. Price

4

1 reference

Nick Curzen

8

1 reference

Elisabeth Mahla

13

1 reference

Sunil V. Rao

17

1 reference

language of work or name

1 reference

17 December 2013

1 reference

Journal of the American College of Cardiology

published in

1 reference

volume

62

1 reference

page(s)

2261-73

1 reference

issue

24

1 reference

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Clopidogrel efficacy and cigarette smoking status.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Association between bleeding events and in-hospital mortality after percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleed

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Platelet function monitoring in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogr

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Assessment of oral antithrombotic therapy by platelet function testing

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Hyperreactive platelets and complications of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Prasugrel in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

1 reference

7 January 2021

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Platelet function testing and prediction of procedural bleeding risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleedin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Clinical end points in coronary stent trials: a case for standardized definitions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Minimizing the risks of anticoagulants and platelet inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021

Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2013.07.101

7 January 2021